VanEck Pharmaceutical ETF (NASDAQ:PPH – Get a rating) was the target of significant short-term interest growth in August. As of August 31, there was short interest totaling 2,280,000 shares, a growth of 31.0% from the total of 1,740,000 shares as of August 15. Based on an average daily trading volume of 178,900 shares, the short-term interest rate ratio is currently 12.7 days.
VanEck Pharmaceutical ETF trades down 0.0%
The NASDAQ PPH traded down $0.02 during Thursday trading hours, hitting $70.70. The company’s stock had a trading volume of 62,148 shares, compared to an average volume of 145,828. The stock has a fifty-day moving average of $74.63 and a 200-day moving average of $76.73 . VanEck Pharmaceutical ETF has a 12-month low of $69.82 and a 12-month high of $84.27.
VanEck Pharmaceutical ETF cuts dividends
The company also recently disclosed a quarterly dividend, which was paid on Friday, July 8. Investors of record on Tuesday, July 5 received a dividend of $0.25. The ex-dividend date was Friday, July 1. This represents an annualized dividend of $1.00 and a yield of 1.41%.
Hedge funds weigh on VanEck Pharmaceutical ETF
Major investors have recently been buying and selling shares of the company. UBS Group AG increased its holdings in VanEck Pharmaceutical ETF by 3,780.8% in the second quarter. UBS Group AG now owns 494,336 shares of the company worth $37,985,000 after purchasing an additional 481,598 shares during the period. Goldman Sachs Group Inc. increased its holdings in VanEck Pharmaceutical ETF by 144.5% in the second quarter. Goldman Sachs Group Inc. now owns 359,687 shares of the company worth $27,638,000 after purchasing an additional 212,560 shares during the period. Noked Israel Ltd acquired a new stake in VanEck Pharmaceutical ETF in the second quarter worth $10,758,000. Phoenix Holdings Ltd. acquired a new stake in VanEck Pharmaceutical ETF in the first quarter worth $7,094,000. Finally, Twelve Points Wealth Management LLC purchased a new equity stake in VanEck Pharmaceutical ETF during the fourth quarter at a value of $4,758,000.
This instant news alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]
Before you consider the VanEck pharma ETF, you’ll want to hear this.
MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market goes viral…and VanEck Pharmaceutical ETF didn’t make the list.
While VanEck Pharmaceutical ETF currently has an “N/A” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the five actions here